The Colorado Division of Workers’ Compensation (DOWC) published a first-of-its-kind evaluation of a medical cannabis reimbursement model called the Alternative Pain Management Program.
Published in the Journal of Occupational and Environmental Medicine (JOEM), this program evaluation explores whether integrating medical cannabis into a highly supervised clinical structure can offer a safe, equitable alternative for specific injured workers.
The program was not a clinical trial to prove or disprove medical cannabis efficacy. Instead, it was a quality improvement project designed to address the self-directed, unstructured use of cannabis, as well access issues, specifically for those who cannot afford to pay for cannabis out of pocket.
Over 200 legacy claimants were evaluated, and one participant was selected for the program, which evaluated meaningful life improvements, adverse events, and opioid tapering. Researchers reported reduced pain, improved physical function, mobility, and quality of life, along with no adverse safety events during the 12-month evaluation.
The authorized treating physician retained absolute clinical responsibility, while a specialized medical cannabis physician managed dosing, titration, and cannabinoid ratios. To minimize respiratory risks and maintain standardized dosing, only specific long-acting oral preparations (like precisely dosed gummies) were approved for reimbursement. The participant used a mobile cannabis-tracking app to log product adherence and report real-time insights to the care team.
Researchers also observed a voluntary 17% reduction in opioid use despite no tapering requirement. According to DOWC, the participant later transitioned off both opioids and THC entirely, relying instead on less psychoactive cannabinoids.
Based on the findings, DOWC concluded that medical cannabis reimbursement may be a viable option for carefully selected workers' compensation patients when administered within a structured and closely monitored treatment model.
Limitations of the study include the single-participant sample, the fact that the participant was retired and not working, and the high level of ongoing clinical advocacy and interagency coordination required to scale this infrastructure. Medical cannabis reimbursement remains a complex and evolving issue in workers' comp. Colorado's findings may influence future discussions around treatment options and coverage policies as stakeholders evaluate alternatives to opioid therapy and federal cannabis policy continues to shift.
